AKT1 and cancer: Multiple recent reviews have discussed the relevance, especially of RhoA and RhoC signaling in cancer, and thus, all three GTPases Rho, Rac, and Cdc42 are potential targets for anticancer drug development (Orgaz et al., 2014; Aspenström, 2018; Svensmark and Brakebusch, 2019; Porazinski et al., 2020).